Paget's disease of bone: Indications for treatment and goals of therapy

Clinical Therapeutics

Volumn 19, Issue 6, 1997, Pages 1309-1329

  Tiegs, Robert D ^a,b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ETIDRONIC ACID; GALLIUM NITRATE; IBANDRONIC ACID; MITHRAMYCIN; PAMIDRONIC ACID; RESIDRONATE; SALCATONIN; TILUDRONIC ACID; UNCLASSIFIED DRUG; ZOLENDRONATE;

BONE CANCER; BONE DEFORMATION; BONE PAIN; BONE REMODELING; DRUG INDUCED DISEASE; FEMUR; GASTROINTESTINAL SYMPTOM; HUMAN; HUMERUS; NAUSEA; NERVE COMPRESSION; PAGET BONE DISEASE; PATHOPHYSIOLOGY; PELVIS; REVIEW; SKULL; SPINE; TIBIA; TREATMENT INDICATION;

EID: 0031426431     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80007-0     Document Type: Review

References (112)

1. Siris E, Kelsy J, Flaster E, et al. Paget's disease in the United States: A survey of 700 patients. J Bone Miner Res. 1988;3: S93. Abstract.
2. Vellenga CJLR, Pauwels EKJ, Bijvoet OLM, et al. Untreated Paget's disease of bone studied by scintigraphy. Radiology. 1984;153:799-805.
3. Meunier PJ, Salson C, Mathieu L, et al. Skeletal distribution and biochemical parameters of Paget's disease. Clin Orthop Relat Res. 1987;217:37-44.
4. Dalinka MK, Aronchick JM, Haddad JG. Paget's disease. Orthop Clin North Am. 1983;4:3-19.
5. Paget J. On a form of chronic inflammation of bones. Trans Med Chir Soc Lond. 1877;60:37-63.
6. Singer FR, Krane SM. Paget's disease of bone. In: Avioli LV, Krane SM, eds. Metabolic Bone Disease. 2nd ed. Philadelphia: WB Saunders; 1990:546-615.
7. Lawrence JS. Paget's disease in population samples. Ann Rheum Dis. 1970;29: 562. Abstract.
8. Detheridge GM, Guyer PB, Barker DJP. European distribution of Paget's disease of bone. BMJ. 1982;285:1005-1008.
9. Barker DJP. The epidemiology of Paget's disease of bone. Br Med Bull. 1984;40: 396-400.
10. Dolev E, Samuel R, Foldes J, et al. Some epidemiological aspects of Paget's disease in Israel. Semin Arthritis Rheum. 1994; 23:228. Abstract.
11. Mautalen C, Pumarino H, Blanco MC, et al. Paget's disease: The South American experience. Semin Arthritis Rheum. 1994; 23:226-227.
12. Siris ES, Canfield RE. Paget's disease of bone. In: Becker KL, ed. Principles and Practice of Endocrinology and Metabolism. Philadelphia: JB Lippincott; 1990: 504-512.
13. Sofaer JA, Holloway SM, Emery AE. A family study of Paget's disease of bone. J Epidemiol Community Health. 1983;37: 226-231.
14. Siris ES, Ottman R, Flaster E, Kelsey JL. Familial aggregation of Paget's disease of bone. J Bone Miner Res. 1991;6:495-500.
15. Morales-Piga AA, Rey-Rey JS, Corres-Gonzalez, J, et al. Frequency and characteristics of familial aggregation of Paget's disease of bone. J Bone Miner Res. 1995;10:663-670.
16. Osterberg PH, Wallace RGH, Adams DA, et al. Familial expansile osteolysis. J Bone Joint Surg Br. 1988;70B:255-260.
17. Crone MD, Wallace RGH. The radiographic features of familial expansile osteolysis. Skeletal Radiol. 1990;19:245-250.
18. Dickson GR, Shirodria PV, Kanis JA, et al. Familial expansile osteolysis: A morphological, histomorphometric and serological study. Bone. 1991;12:331-338.
19. Wallace RGH, Barr RJ, Osterberg PH, Mollan RAB. Familial expansile osteolysis. Clin Orthop Relat Res. 1989;248: 265-277.
20. Hughes AE, Shearman AM, Weber JL, et al. Genetic linkage of familial expansile osteolysis to chromosome 18q. Hum Mol Genet. 1994;3:359-361.
21. Rebel A, Bregeon C, Basle M, et al. Osteoclastic inclusions in Paget's disease of bone. Rev Rhum Mal Osteo-Articulaires. 1974;42:637-641.
22. Mills BG, Singer FR. Nuclear inclusions in Paget's disease of bone. Science. 1976; 194:201-202.
23. Cartwright EJ, Gordon MT, Freemont AJ, et al. Paramyxoviruses and Paget's disease. J Med Virol. 1993;40:133-141.
24. Mu Y, Miyauchi Y, Honoki K, et al. Electron microscopic evidence of a viral nature for osteoclastic inclusions in Paget's disease of bone. Virchows Arch. 1994;424: 99-104.
25. Rebel A, Basle M, Pouplard A, et al. Viral antigens in osteoclasts from Paget's disease of bone. Lancet. 1980;2:344-346.
26. Basle MF, Russell WC, Goswami KKA, et al. Paramyxovirus antigens in osteoclasts from Paget's bone tissue detected by mononuclear antibodies. J Gen Virol. 1985;66:2103-2110.
27. Mills BG, Singer FR, Weiner LP, Holst PA. Immunohistological demonstration of respiratory syncytial virus antigens in Paget's disease of bone. Proc Natl Acad Sci USA. 1981;78:1209-1213.
28. Pringle CR, Wilkie ML, Elliott RM. A survey of respiratory syncytial virus and parainfluenza virus type 3 neutralizing and immunoprecipitating antibodies in relation to Paget's disease. J Med Virol. 1985; 17:377-386.
29. Basle MF, Fournier JG, Rozenblatt S, et al. Measles virus RNA detected in Paget's bone tissue by in situ hybridisation. J Gen Virol. 1986;67:907-913.
30. Ralston SH, Digiovine FS, Gallacher SJ, et al. Failure to detect paramyxovirus sequences in Paget's disease of bone using the polymerase chain reaction. J Bone Miner Res. 1991;6:1243-1248.
31. Birch MA, Taylor W, Fraser WD, et al. Absence of paramyxovirus RNA in cultures of pagetic bone cells and in pagetic bone. J Bone Miner Res. 1994;9:11-16.
32. Nuovo MA, Nuovo GJ, MacConnell P, et al. In situ analysis of Paget's disease of bone for measles-specific PCR amplified cDNA. Diagn Mol Pathol. 1992;1:256-265.
33. Roodman GD. Biology of the osteoclast in Paget's disease. Semin Arthritis Rheum. 1994;23:235-236.
34. Reddy SV, Singer FR, Roodman GD. Bone marrow mononuclear cells from patients with Paget's disease contain measles virus nucleocapsid messenger ribonucleic acid that has mutations in a specific region of the sequence. J Clin Endocrinol Metab. 1995;80:2108-2111.
35. Schajowicz E, Ubios AM, Santini Araujo E, Cabrini RL. Virus-like intranuclear inclusions in giant cell tumour of bone. Clin Orthop Relat Res. 1985;201:247-250.
36. Mills BG, Yabe H, Singer FR. Osteoclasts in human osteopetrosis contain viral-nucleocapsid-like nuclear inclusions. J Bone Miner Res. 1988;3:101-106.
37. Beneton MNC, Harris S, Kanis JA. Paramyxovirus-like inclusions in two cases ot pyknodysostosis. Bone. 1987;8: 211-217.
38. Bianco P, Silvertrini G, Ballanti P, Bonucci E. Paramyxovirus-like nuclear inclusions identical to those of Paget's disease of bone detected in giant cells of primary oxalosis. Virchows Arch A Pathol Anat Histopathol. 1992;421:427-433.
39. Meunier PJ, Coindre JM, Edouard CM, Arlot ME. Bone histomorphometry in Paget's disease. Arthritis Rheum. 1980;23: 1095-1103.
40. Roodman GD, Kurihara N, Ohsaki Y, et al. Interleukin-6: A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest. 1992;89:46-52.
41. Kurihara N, Bertolini D, Suda T, et al. Interleukin-6 stimulates osteoclast-like multinucleated cell formation in long-term human marrow cultures by inducing IL-I release. J Immumol. 1990;144:426. Abstract.
42. Siris ES. Paget's disease of bone. In: Favus MJ, ed. Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism. 3rd ed. Philadelphia: Lippincott-Raven; 1996:409-419.
43. Schmidek HH. Neurologic and neurosurgical sequelae of Paget's disease of bone. Clin Orthop Relat Res. 1977;27:70-77.
44. Herzberg L, Bayliss E. Spinal-cord syndrome due to noncompressive Paget's disease of bone: A spinal-artery steal phenomenon reversible with calcitonin. Lancet. 1980;2:13-15.
45. Franck WA, Bress NM, Singer FR, Krane SM. Rheumatic manifestations of Paget's disease of bone. Am J Med. 1974;56: 592-603.
46. Wheeler TT, Alberts MA, Dolan TA, McGorray SP. Dental, visual, auditory and olfactory complications in Paget's disease of bone. J Am Geriatr Soc. 1995;43: 1384-1391.
47. Kaplan FS. Paget's disease of bone: Orthopedic complications. Semin Arthritis Rheum. 1994;23:250-252.
48. Dove J. Complete fracture of the femur in Paget's disease of bone. J Bone Jt Surg. 1980;62B:12-17.
49. Nicholas JA, Killoran P. Fracture of the femur in patients with Paget's disease. J Bone Jt Surg. 1965;47A:450-461.
50. Monsell EM, Cody DD, Bone HG, et al. Hearing loss in Paget's disease of bone: The relationship between pure-tone thresholds and mineral density of the cochlear capsule. Hear Res. 1995;83: 114-120.
51. Acar J, Delbarre L, Waynberger M. Les complications cardio-vasculaires de la maladie osseuse de Paget. Arch Mal Coeur. 1968;6:849-868.
52. Poretta CA, Dahlin DC, Janes JM. Sarcoma in Paget's disease of bone. J Bone Jt Surg. 1957;39:1313-1329.
53. Wick MR, Siegal GP, Unni KK, et al. Sarcomas of bone complicating osteitis deformans (Paget's disease). Am J Surg Pathol. 1981;5:47-59.
54. Huvos AG, Butler A, Bretsky SS. Osteogenic sarcoma associated with Paget's disease of bone: A clinicopathologic study of 65 patients. Cancer. 1983;52:1489-1495.
55. Upchurch KS, Simon LS, Schiller AL, et al. Giant cell reparative granulomas of Paget's disease of bone: A unique clinical entity. Ann Intern Med. 1983;98:35-40.
56. Schajowicz F, Slullitel I. Giant-cell tumor associated with Paget's disease of bone. J Bone Jt Surg. 1966;48A:1340-1349.
57. Jacobs TP, Michelsen J, Polay J, et al. Giant cell tumor in Paget's disease of bone. Familial and geographic clustering. Cancer. 1979;44:742-747.
58. Siris E, Kelsey J, Plaster E, et al. Environmental exposures and medical histories in Paget's disease. J Bone Miner Res. 1988;3:593. Abstract.
59. Posen S, Clifton-Bligh P, Wilkinson M. Paget's disease of bone and hyperparathyroidism: Coincidence or causal relationship? Calcif Tissue Res. 1978;26:107-109.
60. Lyles KW, Gold DT, Newton RA, et al. Peyronie's disease is associated with Paget's disease of bone. J Bone Miner Res. 1997;12:929-934.
61. Walton RJ, Preston CJ, Bartlett M, et al. Biochemical measurements in Paget's disease of bone. Eur J Clin Invest. 1977; 7:37-39.
62. Alvarez I, Guanebens N, Peris P, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res. 1995;10:458-465.
63. Blumsohn A, Naylor KE, Assiri AM, Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget's disease. Clin Chem. 1994;41:1592-1598.
64. Delmas PD, Demiaux B, Malaval I, et al. Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone. Calcif Tissue Int. 1986; 38:60-61.
65. Uebelhart D, Ginetys E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium crosslinks. A new marker of bone resorption in metabolic bone disease. Bone Miner. 1990;8:87-96.
66. Papapoulos SE, Frolich M. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption. J Clin Endocrinol Metab. 1996; 81:3993-3997.
67. Harris DJ, Fornasier VL. An ivory vertebra: Monostotic Paget's disease of bone. Clin Orthop Relat Res. 1978;136:173-175.
68. Jaffe HL. Atypical form of Paget's disease appearing as generalized osteosclerosis. Arch Pathol Lab Med. 1933;16:1-26.
69. Meunier PJ, Chapuy MC, Delmas P, et al. Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy: Effects on biochemical parameters and bone histomorphometry. Am J Med. 1987;82(Suppl 2A): 71-78.
70. Bombassei GJ, Yocono M, Raisz LG. Effects of intravenous pamidronate therapy on Paget's disease of bone. Am J Med Sci. 1994;308:226-233.
71. Siris ES. Indications for medical treatment of Paget's disease of bone. In: Singer FR, Wallach S, eds. Paget's Disease of Bone. Clinical Assessment, Present and Future Therapy. New York: Elsevier; 1991:44-56.
72. Delmas PD, Meunier PJ. The management of Paget's disease of bone. NEJM. 1997; 336:558-566.
73. Singer FR, Keutman HT, Neer RM, et al. Pharmacologic effects of salmon calcitonin in man. In: Talmage RV, Munson PL, eds. Calcium, Parathyroid Hormone and the Calcitonins. Amsterdam: Excerpta Medicu Foundation; 1972:89-96.
74. DeRose J, Singer F, Avramides A, et al. Response of Paget's disease to porcine and salmon calcitonin. Effects of long term treatment. Am J Med. 1974;47:9-15.
75. Singer FR, Fredericks RS, Minkin C. Salmon calcitonin therapy for Paget's disease of bone: The problem of acquired clinical resistance. Arthritis Rheum. 1980; 23:1148-1154.
76. Singer FR, Ginger K. Resistance to calcitonin. In: Singer FR, Wallach S, eds. Paget's Disease of Bone. Clinical Assessment, Present and Future Therapy. New York: Elsevier; 1991:75-85.
77. Gonzalez D, Vega E, Ghiringhelli G, Mautalen C. Comparison of the acute effect of the intranasal and intramuscular administration of salmon calcitonin in Paget's disease. Calcif Tissue Int. 1987;41:313-315.
78. Rogers MJ, Russell RG. Mechanisms of bisphosphonates as inhibitors of bone resorption. In: Sharpe PT, ed. The Molecular Biology of Paget's Disease. Austin, Tex: R.G. Landes Co.; 1996:147-168.
79. Rodan GA, Fleisch HA. Bisphosphonates: Mechanisms of action. J Clin Invest. 1996; 97:2692-2696.
80. Fleisch H. Bisphosphonates: Pharmacokinetics. In: Bisphosphonates in Bone Disease. 3rd ed. Berne, Switzerland: Parthenon Publishing Group; 1997:58-62.
81. Delmas PD, Chapuy MC, Vignon E, et al. Long-term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metab. 1982;54:837-844.
82. Gray RE, Yates AJ, Preston CJ, et al. Duration of effect of oral diphosphonate therapy in Paget's disease of bone. Q J Med. 1987;64:755-767.
83. Patel S, Stone MD, Coupland C, Hosking DJ. Determinants of remission of Paget's disease of bone. J Bone Miner Res. 1993; 8:1467-1473.
84. Mazières B, Ahmed I, Moulinier L, et al. Pamidronate infusions for the treatment of Paget's disease of bone: Value of a return to normal of alkaline phosphatase levels. Rev Rhum Engl Ed. 1996;63:36-43.
85. Altman RD, Johnston CC, Khairi MRA, et al. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). NEJM. 1973;289:1379-1384.
86. Canfield R, Rosner W, Skinner J, et al. Diphosphonate therapy of Paget's disease of bone. J Clin Endocrinol Metab. 1977; 44:96-106.
87. Meunier PJ, Ravault A. Treatment of Paget's disease with etidronate disodium. In: Singer FR, Wallach S, eds. Paget's Disease of bone. Clinical Assessment, Present and Future Therapy. New York: Elsevier; 1991:86-99.
88. Khairi MRA, Altman RD, DeRosa GP, et al. Sodium etidronate in the treatment of Paget's disease of bone. Ann Intern Med. 1977;87:656.
89. Evans RA, MacDonald D. Diphosphonates and painful feet. Aust New Zealand J Med. 1983;13:175-176.
90. Johnston CC Jr, Altman RD, Canfield RD, et al. Review of fracture experience during treatment of Paget's disease of bone with etidronate disodium (EHDP). Clin Orthop Relat Res. 1983;172:186-194.
91. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporosis Int. 1994;4:320-322.
92. Siris ES. Perspectives: A practical guide to the use of pamidronate in the treatment of Paget's disease. J Bone Miner Res. 1994;9:303-304.
93. Vega E, Gonzalez D, Ghiringhelli G, Mautalen C. Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's disease. J Bone Miner Res. 1987;2: 267-271.
94. Thiebaud D, Jaeger P, Gobelet C, et al. A single infusion of the bisphosphonate AH-PrBP (APD) as treatment of Paget's disease of bone. Am J Med. 1988;85: 207-212.
95. Delmas PD, Casez JP, Arlot MA, et al. Long term effects of intravenous (IV) aminopropylidene diphosphonate (APD) in patients with refractory Paget's disease of bone. Calcif Tissue Int. 1981;44 (Suppl):S104. Abstract.
96. Adamson BB, Gallacher SJ, Byars J, et al. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet. 1993;342:1459-1460.
97. Cundy T, Wattie D, King AR. High-dose pamidronate in the management of resistant Paget's disease. Calcif Tissue Int. 1996;58:6-8.
98. Mautalen CA, Gonzalez D, Ghiringhelli G. Efficacy of the bisphosphonate APD in the control of Paget's disease. Bone. 1985;6:429-432.
99. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol. 1994;118: 220-224.
100. O'Donnel NP, Rao GP, Aguis-Fernandez A. Paget's disease: Ocular complications of disodium pamidronate treatment. Br J Clin Prac. 1995;49:272-273.
101. Reid IR, Mills DA, Wattie DJ. Ototoxicity associated with intravenous bisphosphonate administration. Calcif Tissue Int. 1995;56:584-585.
102. Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, et al. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res. 1995;10:956-962.
103. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab. 1996;81:961-967.
104. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. NEJM. 1996;335:1016-1021.
105. McClung MR, Tou CK, Goldstein NH, Picot C. Tiludronate therapy for Paget's disease of bone. Bone. 1995;17:493-496.
106. Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum. 1994;38:851-858.
107. Chines A, Bekker P, Clarke P, Hosking D. Reduction of bone pain and alkaline phosphatase in patients with severe Paget's disease of bone following treatment with residronate. J Bone Miner Res. 1996:11(Suppl 1):S371. Abstract.
108. Arden-Cordone M, Siris ES, Lyles KW, et al. Antiresorptive effect of a single infusion of microgram quantities of zolendronate in Paget's disease of hone. Calcif Tissue Int. 1997;60:415-418.
109. Knaus J, Grauer A, Seihel MJ, Ziegler R. Treatment of Paget's disease of hone with the new bisphosphonate ibandronate (BM 21.0955) by intravenous injection and continuous infusion. Bone. 1995; 17:614. Abstract.
110. Ryan WG, Schwartz TB, Perlia CP. Effects of mithramycin on Paget's disease of bone. Ann Intern Med. 1969;70: 549-557.
111. Ryan WG, Schwartz TB. Mithramycin treatment of Paget's disease of bone: Exploration of combined mithramycinEHDP therapy. Arthritis Rheum. 1980; 23:1155-1161.
112. Bockman RS, Wilhelm F, Siris E, et al. A multicenter trial of low dose gallium nitrate in patients with advanced Paget's disease of bone. J Clin Endocrinol Metab. 1995;80:595-602.